je.st
news
Tag: infection
Rodman Media announces webinar on \'Hospital Acquired Infection\'
2014-04-21 07:00:00| Label and Narrow Web Breaking News
The one-hour webinar will take place on May 22.
Tags: media
hospital
acquired
infection
Wisconsin Issues Warning Against Intentional PEDV Infection
2014-04-16 16:33:00| National Hog Farmer
Source: Wisconsin Department of Agriculture, Trade and Consumer Protection Biosecurity is the best way to prevent spread of porcine epidemic diarrhea virus (PEDV) advises Paul McGraw, DVM, Wisconsin State Veterinarian. This advice comes after the Wisconsin Department of Agriculture, Trade and Consumer Protection (DATCP) received information that some swine producers are considering transporting virus-laden material from premises with diseased pigs in an effort to build the immunity of their own herds against the disease. read more
Tags: issues
warning
wisconsin
infection
Mercks Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
2014-04-11 07:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Initiation of C-EDGE Phase 3 Program WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: activity
combination
patients
therapy
Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Nave Patients with Genotype 1 Infection
2014-04-10 07:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Advancement into Phase 3 Trials WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestors:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
results
studies
patients
TRU-D SmartUVC(TM) to Showcase Infection Prevention Tracking Technology at AORN Surgical ...
2014-03-26 05:00:00| Industrial Newsroom - All News for Today
iTRU-D proves to be valuable tool for thorough disinfection of operating suites<br /> <br /> CHICAGO - TRU-D SmartUVC™ will showcase its exclusive cloud-based infection prevention tracking technology, iTRU-D, at the Association for periOperative Registered Nurses Surgical Conference and Expo 2014 in Chicago, Ill., March 30 through April 1. Company leadership will demonstrate how TRU-D and the new innovative technology work together to provide customized reports, including infection ...This story is related to the following:SoftwareSearch for suppliers of: Business Intelligence Software |
Tags: technology
tracking
prevention
infection
Sites : [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »